These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. Mato AR; Roeker LE; Jacobs R; Hill BT; Lamanna N; Brander D; Shadman M; Ujjani CS; Yazdy MS; Perini GF; Pinilla-Ibarz JA; Barrientos J; Skarbnik AP; Torka P; Pu JJ; Pagel JM; Gohil S; Fakhri B; Choi M; Coombs CC; Rhodes J; Barr PM; Portell CA; Parry H; Garcia CA; Whitaker KJ; Winter AM; Sitlinger A; Khajavian S; Grajales-Cruz AF; Isaac KM; Shah P; Akhtar OS; Pocock R; Lam K; Voorhees TJ; Schuster SJ; Rodgers TD; Fox CP; Martinez-Calle N; Munir T; Bhavsar EB; Bailey N; Lee JC; Weissbrot HB; Nabhan C; Goodfriend JM; King AC; Zelenetz AD; Dorsey C; Bigelow K; Cheson BD; Allan JN; Eyre TA Clin Cancer Res; 2020 Jul; 26(14):3589-3596. PubMed ID: 32198151 [TBL] [Abstract][Full Text] [Related]
52. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Thompson PA; Burger JA Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406 [TBL] [Abstract][Full Text] [Related]
53. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P; Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597 [TBL] [Abstract][Full Text] [Related]
54. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis. Molica S; Baumann T; Giannarelli D Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324 [No Abstract] [Full Text] [Related]
55. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia. Miao Y; Xu W; Li J Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396 [TBL] [Abstract][Full Text] [Related]
56. Managing toxicities of Bruton tyrosine kinase inhibitors. Lipsky A; Lamanna N Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):336-345. PubMed ID: 33275698 [TBL] [Abstract][Full Text] [Related]
57. MARCKS affects cell motility and response to BTK inhibitors in CLL. Beckmann L; Berg V; Dickhut C; Sun C; Merkel O; Bloehdorn J; Robrecht S; Seifert M; da Palma Guerreiro A; Claasen J; Loroch S; Oliverio M; Underbayev C; Vaughn L; Thomalla D; Hülsemann MF; Tausch E; Fischer K; Fink AM; Eichhorst B; Sickmann A; Wendtner CM; Stilgenbauer S; Hallek M; Wiestner A; Zahedi RP; Frenzel LP Blood; 2021 Aug; 138(7):544-556. PubMed ID: 33735912 [TBL] [Abstract][Full Text] [Related]
58. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax. Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791 [TBL] [Abstract][Full Text] [Related]
59. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Friedberg JW; Sharman J; Sweetenham J; Johnston PB; Vose JM; Lacasce A; Schaefer-Cutillo J; De Vos S; Sinha R; Leonard JP; Cripe LD; Gregory SA; Sterba MP; Lowe AM; Levy R; Shipp MA Blood; 2010 Apr; 115(13):2578-85. PubMed ID: 19965662 [TBL] [Abstract][Full Text] [Related]
60. Time-limited, Combined Regimen in Chronic Lymphocytic Leukemia: A Promising Strategy to Achieve a Drug Holiday. Jiang R; Li JY; Zhu HY Curr Med Sci; 2021 Jun; 41(3):431-442. PubMed ID: 34181208 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]